ADC Therapeutics (ADCT) Current Leases (2019 - 2023)

ADC Therapeutics has disclosed Current Leases across 5 years of filings, most recently posting $1.5 million for Q4 2023.

• Current Leases for Q4 2023 came in at $1.5 million, up 33.73% year-over-year; the trailing twelve-month figure through Dec 2023 was $1.5 million (up 33.73% YoY), and the FY2023 annual result was $1.5 million, up 33.73% from the prior year.
• Current Leases came in at $1.5 million for Q4 2023 at ADC Therapeutics, up from $1.1 million in the prior quarter.
• In the past five years, Current Leases ranged from a high of $1.5 million in Q4 2023 to a low of $924000.0 in Q4 2019.
• The 5-year median for Current Leases is $1.0 million (2021), against an average of $1.1 million.
• Across the five-year window, Current Leases rose 2.69% in 2021 and surged 33.73% in 2023, its largest moves.
• ADC Therapeutics' Current Leases stood at $924000.0 in 2019, then gained by 8.44% to $1.0 million in 2020, then rose by 2.69% to $1.0 million in 2021, then increased by 6.61% to $1.1 million in 2022, then soared by 33.73% to $1.5 million in 2023.
• The last three Current Leases figures came in at $1.5 million (Q4 2023), $1.1 million (Q4 2022), and $1.0 million (Q4 2021), per Business Quant data.